St. Luke's Hospital & Health Network: Allovectin-7(R) May Offer Patients a New Option for Advanced Melanoma

BETHLEHEM, Pa.--(BUSINESS WIRE)--Internationally-recognized melanoma investigator Sanjiv S. Agarwala, MD, Chief, Medical Oncology, St. Luke’s Hospital & Health Network, is recruiting patients into a large Phase 3 study to evaluate the safety and effectiveness of Allovectin-7®, an investigational product for advanced melanoma. Serving as sub-investigators are surgical oncologists Lee B. Riley, MD, PhD, Chief, Surgical Oncology, St. Luke’s Hospital & Health Network, and Darius C. Desai, MD.